QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

TVTX

QT68Travere Therapeutics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
55.15
+1.01+1.87%
OverviewShort InterestFilings
TVTXQT68Travere Therapeutics, Inc.·NASDAQ
OverviewShort InterestFilings
55.15+1.87%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-0.53
Insider Own2.30%
Shs Outstand92.99M
Perf Week12.76%
Market Cap5.03BForward P/E22.10EPS next Y2.50Insider Trans0.26%Shs Float-Perf Month30.50%
Enterprise Value5.28BPEG-EPS next Q-0.08Inst Own-Short Float-Perf Quarter98.95%
Income-21648933.00P/S9.39EPS this Y137.61%Inst Trans-Short Ratio-Perf Half Y53.84%
Sales536.20MP/B50.38EPS next Y1151.84%ROA-3.86%Short Interest-Perf YTD44.33%
Book/sh1.06P/C125.56EPS next 5Y129.73%ROE-26.79%52W High55.99 -1.50%Perf Year291.41%
Cash/sh2.85P/FCF288.78EPS past 3/5Y-ROIC-13.09%52W Low13.88 297.33%Perf 3Y-
Dividend Est.-EV/EBITDA137.11Sales past 3/5Y65.15% 19.92%Gross Margin93.95%Volatility2.62% 3.18%Perf 5Y-
Dividend TTM-EV/Sales9.85EPS Y/Y TTM94.61%Oper. Margin-10.64%ATR (14)2.36Perf 10Y-
Dividend Ex-Date-Quick Ratio3.08Sales Y/Y TTM130.04%Profit Margin-4.00%RSI (14)72.58Recom2.17
Dividend Gr. 3/5Y-Current Ratio3.13EPS Q/Q17.02%SMA2014.76%Beta1.75Target Price56.67
Payout0.00%Debt/Eq3.32Sales Q/Q54.88%SMA5025.91%Rel Volume2.48Prev Close54.14
Employees385LT Debt/Eq2.81EarningsAug 05SMA20064.06%Avg Volume2.66MPrice55.15
IPO DateNov 08, 2012Option/ShortYes / YesEPS/Sales Surpr.-30.00% -6.62%Net Debt/EBITDA6.47Volume6,587,046Change1.87%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-02-26ReiteratedH.C. Wainwright$18 → $67
Apr-14-26ReiteratedPiper SandlerNeutral$12 → $49
Apr-14-26ReiteratedGuggenheimBuy$49 → $54
Jan-14-26ReiteratedGuggenheimBuy$23 → $49
Sep-10-25ReiteratedJefferies$35
Oct-31-24ReiteratedEvercore ISI$30 → $33
Oct-21-24UpgradeWells FargoEqual Weight → Overweight$28 → $27
Oct-10-24ReiteratedEvercore ISI$12 → $30
Oct-09-24ReiteratedBank of America Securities$18 → $20
Oct-01-24ReiteratedBarclaysOverweight$18
Latest News
Jun-18-26
Jun-18-2611:27AM
Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $60Benzinga
Jun-15-26
Jun-15-2601:47PM
Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $70Benzinga
Jun-12-26
Jun-12-2609:40AM
Wells Fargo Maintains Overweight on Travere Therapeutics, Raises Price Target to $65Benzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue536491233
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A34108
Gross Profit503480225
Selling, General and Administrative Excl. Other344337264
Research and Development216206283
Other Operating Expense102
Operating Income-57-63-324
Interest Expense101111
Unusual Expense
———
Non-Operating Income (Expense)-23-24-14
Net Income Before Taxes-45-49-321
Income Taxes110
Consolidated Net Income-21-26-322
Net Income From Continuing Operations-46-50-321
Net Income-21-26-322
EPS (Recurring)-0.49-0.56-4.08
EPS (Basic, Before Extraordinaries)-0.49-0.56-4.08
EPS (Diluted)-0.53-0.56-4.08
EBITDA3822-266
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio9.476.93—
Gross Margin93.8497.7696.57
Operating Margin-10.63-12.83-139.06
Net Margin-3.92-5.30-138.20
Shares Outstanding928979
Market Capitalization5,0743,401—
Operating Lease Expense
———
Insider Trading Volume
$60.19$56.45$52.71$48.97$45.23● Close Price0.00M2.79M5.59M8.38M11.18MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Baynes Roy D.DirectorJun 12 '26Sale50.004,500225,00041,500Jun 16 12:00 AM
Coughlin TimothyDirectorJun 12 '26Sale50.0710,000500,74756,250Jun 16 12:00 AM
Coughlin TimothyDirectorJun 12 '26Option Exercise26.5220,000530,40066,250Jun 16 12:00 AM
Baynes Roy D.DirectorJun 12 '26Option Exercise21.389,000192,42046,000Jun 16 12:00 AM
Coughlin TimothyDirectorMay 15 '26Sale43.493,250141,34352,250May 19 12:00 AM
Cline Christopher R.CHIEF FINANCIAL OFFICERMay 06 '26Sale43.9531013,625118,658May 06 12:00 AM
Dube Eric MCHIEF EXECUTIVE OFFICERMay 06 '26Sale43.9522,500988,875432,886May 06 12:00 AM
ROTE WILLIAM E.Chief Research OfficerMay 06 '26Sale43.952,763121,434115,474May 06 12:00 AM
REED ELIZABETH EChief Legal Officer and GCMay 06 '26Sale43.952,07691,240105,211May 06 12:00 AM
Inrig JulaCHIEF MEDICAL OFFICERMay 06 '26Sale43.9531113,668113,238May 06 12:00 AM
Cline Christopher R.CHIEF FINANCIAL OFFICERMay 05 '26Sale46.652,181101,744118,968May 06 12:00 AM
REED ELIZABETH EChief Legal Officer and GCMay 05 '26Sale46.652,174101,417107,287May 06 12:00 AM
Baynes Roy D.DirectorMay 05 '26Option Exercise18.279,000164,43042,000May 06 12:00 AM
Baynes Roy D.DirectorMay 05 '26Sale46.654,500209,92537,500May 06 12:00 AM
Heerma PeterCHIEF COMMERCIAL OFFICERMay 05 '26Sale46.652,174101,417140,684May 06 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR